ATOS ATOSSA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1488039 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-14.8%
TTM EPS YoY31.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-96.9%
ROA-82.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets17.8%
Debt / equity0.00x
Current ratio5.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio1.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $3.38M | $4.90M | $4.78M | $6.16M | $5.37M | $5.50M | $4.16M | $3.40M |
| SG&A expense | $2.52M | $3.80M | $5.09M | $5.28M | $3.88M | $3.54M | $3.26M | $3.75M |
| Operating income | -$5.90M | -$8.69M | -$9.87M | -$11.44M | -$9.25M | -$9.04M | -$7.41M | -$7.15M |
| Pretax income | -$5.64M | -$8.49M | -$9.59M | -$10.94M | -$8.69M | -$8.42M | -$6.72M | -$6.35M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$5.64M | -$8.49M | -$9.59M | -$10.94M | -$8.69M | -$8.42M | -$6.72M | -$6.35M |
| EBITDA | -$5.89M | -$8.69M | -$9.87M | -$11.43M | -$9.25M | -$9.04M | -$7.41M | -$7.15M |
| EPS (basic) | -0.56 | -0.95 | -1.11 | — | -1.01 | -0.98 | -0.78 | — |
| EPS (diluted) | -0.56 | -0.95 | -1.11 | — | -1.01 | -0.98 | -0.78 | — |
| Weighted avg. shares (diluted) | 9.99M | 8.91M | 8.62M | — | 8.62M | 8.62M | 8.62M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $20.57M | $26.09M | $31.72M | $41.30M | $51.84M | $57.86M | $65.12M | $71.08M |
| Current assets | $25.18M | $31.01M | $36.67M | $45.62M | $55.68M | $62.52M | $68.74M | $74.46M |
| Total assets | $26.45M | $32.28M | $37.94M | $47.61M | $58.01M | $64.52M | $70.75M | $76.44M |
| Current liabilities | $4.71M | $5.45M | $7.46M | $8.26M | $8.22M | $6.82M | $5.42M | $4.97M |
| Total liabilities | $4.71M | $5.45M | $7.46M | $8.26M | $8.22M | $6.82M | $5.42M | $4.97M |
| Shareholders' equity | $21.74M | $26.83M | $30.49M | $39.35M | $49.79M | $57.70M | $65.32M | $71.48M |
| Shares outstanding | 9.98M | 9.98M | 8.61M | 8.61M | 129.17M | 129.17M | 129.17M | 8.61M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.52M | -$9.64M | -$9.58M | -$10.54M | -$6.00M | -$7.26M | -$5.96M | -$7.05M |
| Capital expenditure | $0 | $0 | $0 | $7,000 | $7,000 | $0 | $9,000 | $0 |
| Free cash flow | -$5.52M | -$9.64M | -$9.58M | -$10.55M | -$6.01M | -$7.26M | -$5.97M | -$7.05M |
| Investing cash flow | $0 | $0 | $0 | -$7,000 | -$7,000 | $0 | -$9,000 | $0 |
| Financing cash flow | $0 | $4.02M | $0 | $0 | $0 | $0 | $0 | $3.37M |
| Depreciation & amortization | $4,000 | $4,000 | $4,000 | $4,000 | $4,000 | $4,000 | $4,000 | $4,000 |
| Stock-based compensation | $547,000 | $815,000 | $722,000 | $503,000 | $784,000 | $796,000 | $563,000 | $774,000 |
Free plan shows the latest 8 periods; Pro shows all 61 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.